H. Lundbeck A / S Denmark

The full results of the open label extension (OLE) of the Phase 1b/2a PACIFIC trial investigating bexicaserin for the treatment of patients with Developmental and Epileptic Encephalopathies (DEEs), will be presented for the first time at the International Epilepsy Annual Congress1DEEs are the most severe rare epilepsies, characterized by drug-resistant seizures, frequent epileptic activity on EEG and developmental slowing or regression2Bexicaserin, which has been granted Breakthrough Therapy designation by the FDA, demonstrated reductions in countable and total motor seizure frequency in the extension study comparable to reductions seen in the Phase 1b/2a PACIFIC trial, reinforcing durability of response and validating its progression to Phase 3 trials1Additional data will be presented from the audiogenic seizure model and the GAERS absence epilepsy model, investigating sudden unexpected death in epilepsy (SUDEP), and seizure reduction respectively.3,4and connect with us via LinkedIn.

References:

Dlugos DJ, et al. Poster presentation: International Epilepsy Congress 2025.Sheffer IE, et al. Epilepsia. 2025;00:1-10Vermudez S, et al. Platform Presentation: International Epilepsy Congress 2025.Vermudez S, et al. Poster Presentation: International Epilepsy Congress 2025.American Academy of Neurology Annual Meeting 2025. Safety, Tolerability, and Efficacy of Bexicaserin in a Cohort of Participants with Developmental and Epileptic Encephalopathies: Interim Results of a Phase 1b/2a PACIFIC Study Open-Label Extension.Donner EJ, et al. Pediatric Neurology, 2017;70:7-15Daquin G, Bonini F. Revue Neurologique, 2024;180(4):256-270https://clinicaltrials.gov/study/NCT06660394https://clinicaltrials.gov/study/NCT06719141Ngoc Minh Le et al. Poster presentation: International Epilepsy Congress 2025Kaye R, et al. Efficacy and safety of bexicaserin (LP352) in adolescent and adult participants with developmental and epileptic encephalopathies: Results of the phase 1b/2a PACIFIC study. Presented at the Annual Meeting of the American Academy of Neurology; April 13-18, 2024

Contacts:
H. Lundbeck A/S
Ottiliavej 9, 2500 Valby, Denmark
+45 3630 1311
info@lundbeck.com 

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/h--lundbeck-a-s/r/lundbeck-to-present-new-data-on-bexicaserin-at-upcoming-congress--highlighting-long-term-impact-on-s,c4222334

The following files are available for download:

https://mb.cision.com/Main/18215/4222334/3624393.pdf

Bexicaserin IEC curtain raiser Final

 

 

 

View original content:https://www.prnewswire.co.uk/news-releases/lundbeck-to-present-new-data-on-bexicaserin-at-upcoming-congress-highlighting-long-term-impact-on-seizure-frequency-in-patients-with-rare-epilepsy-302537473.html